Gossamer Bio Statistics
Want to see GOSS full AI Analyst Report?
Gossamer Bio (GOSS) Stock Statistics & Valuation Metrics
Total Valuation
Gossamer Bio has a market cap or net worth of $59.70M. The enterprise value is $37.16M.
- Market Cap
- $59.70M
- Enterprise Value
- $37.16M
Share Statistics
Gossamer Bio has 6,110,584 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,110,584
- Owned by Insiders
- 1.86%
- Owned by Institutions
- 45.21%
Financial Efficiency
Gossamer Bio’s return on equity (ROE) is 1.39 and return on invested capital (ROIC) is -148.67%.
- Return on Equity (ROE)
- 1.39
- Return on Assets (ROA)
- -0.99
- Return on Invested Capital (ROIC)
- -148.67%
- Return on Capital Employed (ROCE)
- -1.50
- Revenue Per Employee
- 299.20K
- Profits Per Employee
- -1.05M
- Employee Count
- 162
- Asset Turnover
- 0.28
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Gossamer Bio is -0.23. Gossamer Bio’s PEG ratio is 0.08.
- PE Ratio
- -0.23
- PS Ratio
- 1.22
- PB Ratio
- -0.31
- Price to FCF
- -0.40
- Price to Operating Cash Flow
- -0.18
- PEG Ratio
- 0.08
Income Statement
In the last 12 months, Gossamer Bio had revenue of 48.47M and earned -170.37M in profits. Earnings per share was -59.64.
- Revenue
- 48.47M
- Gross Profit
- 47.47M
- Operating Income
- -163.25M
- Pretax Income
- -170.46M
- Net Income
- -170.37M
- EBITDA
- -158.47M
- Earnings Per Share (EPS)
- -59.64
Cash Flow
In the last 12 months, operating cash flow was -162.63M and capital expenditures 0, giving a free cash flow of -162.63M billion.
- Operating Cash Flow
- -162.63M
- Free Cash Flow
- -162.63M
- Free Cash Flow per Share
- -58.93
Dividends & Yields
Gossamer Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -252.98%
- Earnings Yield
- -431.34%
Stock Price Statistics
- Beta
- 1.52
- 52-Week Price Change
- -94.71%
- 50-Day Moving Average
- 10.82
- 200-Day Moving Average
- 31.39
- Relative Strength Index (RSI)
- 47.79
- Average Volume (3m)
- 259.08K
Important Dates
Gossamer Bio upcoming earnings date is Mar 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 12, 2027
- Ex-Dividend Date
- ―
Financial Position
Gossamer Bio as a current ratio of 2.64, with Debt / Equity ratio of -165.29%
- Current Ratio
- 2.64
- Quick Ratio
- 2.64
- Debt to Market Cap
- 0.28
- Net Debt to EBITDA
- -1.04
- Interest Coverage Ratio
- -14.86
Taxes
In the past 12 months, Gossamer Bio has paid -88.00K in taxes.
- Income Tax
- -88.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Gossamer Bio EV to EBITDA ratio is -0.30, with an EV/FCF ratio of -0.38.
- EV to Sales
- 1.17
- EV to EBITDA
- -0.30
- EV to Free Cash Flow
- -0.38
- EV to Operating Cash Flow
- -0.38
Balance Sheet
Gossamer Bio has $57.03M in cash and marketable securities with $39.10M in debt, giving a net cash position of $17.92M billion.
- Cash & Marketable Securities
- $57.03M
- Total Debt
- $39.10M
- Net Cash
- $17.92M
- Net Cash Per Share
- $2.93
- Tangible Book Value Per Share
- -$34.07
Margins
Gross margin is 99.56%, with operating margin of -311.70%, and net profit margin of -235.00%.
- Gross Margin
- 99.56%
- Operating Margin
- -311.70%
- Pretax Margin
- -235.17%
- Net Profit Margin
- -235.00%
- EBITDA Margin
- -383.80%
- EBIT Margin
- -385.55%
Analyst Forecast
The average price target for Gossamer Bio is $110.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $110.00
- Price Target Upside
- 1025.90% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 32.43%
- EPS Growth Forecast
- 7.41%
Scores
- Smart Score
- 5
- AI Score
- 43
